Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation of members of Sensorion’s management in three scientific conferences in July 2022.

Laurent Desire, Ph.D., Sensorion’s Preclinical Development Director, will participate, in-person, in a workshop entitled Gene Therapy for Novel indications, on July 11, 2022 at the 3^rd annual Gene Therapy Neurological Disorders Europe meeting, being held in Paris, France, July 11-13, 2022.

Workshop: Gene Therapy for Novel indications (Laurent Desire’s contribution will focus on the inner ear)
Date: Monday, July 11, 2022
Time: 5 am – 7 am EDT (11 am – 1 pm CEST)
Presenter: Laurent Desire, Ph.D.
Event: Gene Therapy Neurological Disorders Europe

Otmane Boussif, Sc.D., Sensorion’s Chief Technical Officer, will participate virtually in a panel discussion entitled Dealing with Post-Marketing Activities for Cell & Gene Therapy on July 19, 2022, at the 7th Cell & Gene Therapy Summit on July 19-21, 2022. He will also give a presentation on Advancing Gene Therapy for Hearing Disorders: Dual AAV Manufacturing & Control Strategy, on July 21, 2022.

Panel Discussion: Dealing with Post-Marketing Activities for Cell & Gene Therapy
Date: Tuesday, July 19, 2022
Time: 4.20 pm – 5.15 pm SGT (10.20 am – 11.15 am CEST)
Presenter: Otmane Boussif, Sc.D.
Event: 7th Cell & Gene Therapy Summit

Presentation: Advancing Gene Therapy for Hearing Disorders: Dual AAV Manufacturing & Control Strategy
Date: Thursday, July 21, 2022
Time: 3.15 pm – 4 pm SGT (9.15 am – 10 am CEST)
Presenter: Otmane Boussif, Sc.D.
Event: 7th Cell & Gene Therapy Summit

Christine Le Bec, Ph.D., Sensorion’s Head of CMC Gene Therapy, will give a talk on the Characterization of Dual AAV Vector Otoferlin, on July 21, 2022, virtually, at the CASSS Bioassays Symposium, being held in Gaithersburg, MD, USA, July 19-21, 2022.

Presentation: Characterization of Dual AAV Vector Otoferlin
Date: Thursday, July 21, 2022
Time: 2.40 pm – 3.05 pm EDT (8.40 pm – 9.05 pm CEST)
Presenter: Christine Le Bec, Ph.D.
Event: CASSS Bioassays Symposium

About Sensorion

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need.

Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its portfolio combines both small molecule programs and a preclinical portfolio of inner ear gene therapies.

Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 Proof of Concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation.

Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including deafness caused by a mutation of the gene encoding for Otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.

www.sensorion.com

Label: SENSORION
ISIN: FR0012596468
Mnemonic: ALSEN

Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2021 full year financial report published on April 28, 2022, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.

Investor Relations
Catherine Leveau
Head of Investor Relations & Communication
+33 6 72 18 00 22
ir.contact@sensorion-pharma.com

International Media Relations
Consilium Strategic Communications
Mary-Jane Elliott/Jessica Hodgson
+44 7739 788014
+44 7561 424788
Sensorion@consilium-comms.com